Company profile: Phanes Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics for solid tumors and eye diseases, offering PACbody, ATACCbody, and SPECpair platforms for native IgG-like and conjugated bispecific antibodies compatible with conventional monoclonal manufacturing, and a Phase 1 pipeline including PT199 (NSCLC, PDAC), PT886 (metastatic/advanced gastric, gastroesophageal junction, pancreatic adenocarcinoma), and PT217 (advanced refractory DLL3-expressing cancers).
Products and services
- ATACCbody®: Engineers conjugated IgG-like bispecific antibodies with environment-responsive activity to target solid tumors while minimizing cytokine release syndrome risk
- PACbody®: Constructs native IgG-like bispecific antibodies with drug-like properties and manufacturing-ready compatibility with conventional monoclonal antibody manufacturing processes
- SPECpair®: Enables manufacturing of native IgG-like bispecific antibodies with enhanced manufacturability, fitting conventional monoclonal antibody production processes, process-compatible
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phanes Therapeutics
Lymphatica Medtech
HQ: Switzerland
Website
- Description: Provider of medical device development, creating a minimally invasive solution for chronic lymphedema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lymphatica Medtech company profile →
GenomeDx
HQ: Canada
Website
- Description: Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenomeDx company profile →
MetaStat
HQ: United States
Website
- Description: Provider of diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaStat company profile →
Imago BioSciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical drug development focused on novel medicines for managing proliferative diseases of the bone marrow, translating state-of-the-art science and leveraging the skills and experience of its team and the financial commitment of its investors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imago BioSciences company profile →
Cartesian Therapeutics
HQ: United States
Website
- Description: Provider of potent, safer cell therapy in and beyond oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cartesian Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phanes Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phanes Therapeutics
2.2 - Growth funds investing in similar companies to Phanes Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phanes Therapeutics
4.2 - Public trading comparable groups for Phanes Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →